TIA1 and tauopathy: The discovery that these neurodegenerative pathways share a unified mechanism mediated by tau oligomers, TIA1 and SG biology, suggests that therapeutic approaches targeting this pathological mechanism will be able to inhibit both the cell synthesized (intrinsic) and intercellular propagated tau pathways in tauopathy, leading to increased therapeutic efficacy.